TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
+18.81%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$1.18B
AUM Growth
+$1.18B
(+23%)
Cap. Flow
+$77.2M
Cap. Flow
% of AUM
6.54%
Top 10 Holdings %
Top 10 Hldgs %
58.4%
Holding
38
New
6
Increased
2
Reduced
5
Closed
2
Top Buys
| 1 |
Xencor
XNCR
|
$48.8M |
| 2 |
THRD
Third Harmonic Bio
THRD
|
$32.7M |
| 3 |
Fulcrum Therapeutics
FULC
|
$18.7M |
| 4 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$16.9M |
| 5 |
Structure Therapeutics
GPCR
|
$16.2M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$41.8M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$10.7M |
| 3 |
Mineralys Therapeutics
MLYS
|
$8.66M |
| 4 |
C4 Therapeutics
CCCC
|
$5.9M |
| 5 |
SLN
Silence Therapeutics
SLN
|
$4.76M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $138M | 11.73% |
3,670,206
| – | – |
|
2
Dyne Therapeutics
DYN
$1.92B
| $95.2M | 8.07% |
2,650,150
| – | – |
|
3
Cogent Biosciences
COGT
$1.69B
| $75.2M | 6.37% |
6,964,375
| – | – |
|
|
ABVX
4
Abivax
ABVX
$6.12B
| $69.8M | 5.91% |
6,056,596
| – | – |
|
5
Edgewise Therapeutics
EWTX
$1.51B
| $56.4M | 4.78% |
2,112,984
-159,744
| -7% | -$4.26M |
|
|
SLN
6
Silence Therapeutics
SLN
$227M
| $55.2M | 4.67% |
3,033,560
-261,790
| -8% | -$4.76M |
|
7
Savara
SVRA
$567M
| $52.4M | 4.44% |
12,362,205
| – | – |
|
8
Keros Therapeutics
KROS
$618M
| $51.1M | 4.33% |
879,344
| – | – |
|
|
9
Xencor
XNCR
$580M
| $48.8M | 4.14% |
+2,427,138
| New | +$48.8M |
|
10
Tyra Biosciences
TYRA
$675M
| $46.8M | 3.96% |
1,989,103
| – | – |
|
|
11
Structure Therapeutics
GPCR
$1.11B
| $46.7M | 3.95% |
1,063,000
+368,453
| +53% | +$16.2M |
|
12
Ocular Therapeutix
OCUL
$2.12B
| $46.3M | 3.92% |
5,319,148
| – | – |
|
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$2.25B
| $46.2M | 3.92% |
2,890,816
| – | – |
|
14
Tourmaline Bio
TRML
$601M
| $38M | 3.22% |
1,477,593
| – | – |
|
|
THRD
15
DELISTED
Third Harmonic Bio
THRD
| $32.7M | 2.77% |
+2,415,000
| New | +$32.7M |
|
16
Astria Therapeutics
ATXS
$349M
| $30.4M | 2.58% |
2,761,861
| – | – |
|
|
17
Mineralys Therapeutics
MLYS
$1.03B
| $29.9M | 2.53% |
2,470,265
-714,920
| -22% | -$8.66M |
|
18
Kura Oncology
KURA
$686M
| $27.8M | 2.36% |
1,423,642
| – | – |
|
19
Soleno Therapeutics
SLNO
$3.6B
| $27.8M | 2.35% |
550,000
| – | – |
|
|
CMPS
20
Compass Pathways
CMPS
$424M
| $24.3M | 2.06% |
3,858,000
| – | – |
|
21
Disc Medicine
IRON
$2.07B
| $23.9M | 2.03% |
486,957
| – | – |
|
|
22
Fulcrum Therapeutics
FULC
$351M
| $18.7M | 1.59% |
+5,250,000
| New | +$18.7M |
|
|
MBX
23
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $16.9M | 1.43% |
+650,000
| New | +$16.9M |
|
24
Amylyx Pharmaceuticals
AMLX
$836M
| $15M | 1.27% |
+4,643,812
| New | +$15M |
|
25
Adverum Biotechnologies
ADVM
$64.6M
| $14.1M | 1.19% |
2,008,339
-1
| -0% | -$7 |
|